After the Fed released minutes of its last meeting, the bond market signaled it fears the Fed will not be aggressive enough with its rate cutting.Market Insiderread more
The Fed minutes also note that "a couple" members wanted a 50 basis point cut, based primarily on the weak inflation readings.The Fedread more
The inversion is seen by many veteran traders as an important recession omen, though the timing on the eventual downturn is less predictable.Bondsread more
Here's what Nordstrom reported for its fiscal second-quarter earnings.Retailread more
The sexy image that once boosted Victoria's Secret has been haunting L Brands more recently, as women are steering clear of the brand's hot pink, lacy and bejeweled lingerie.Retailread more
See which stocks are posting big moves after the bell.Market Insiderread more
"I'd love to say that the optimistic universe is most likely to prevail, but the talking heads talk endlessly about how a recession is inevitable," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
Read the fine print in your Apple Card contract — one clause means you give up your right to be heard in court.Technologyread more
Federal Reserve members worried over future growth are highly concerned about the U.S.-China tariff battleThe Fedread more
President Donald Trump signed a memorandum on Wednesday to automatically cancel the student loan debt of disabled veterans. More than 25,000 service members will have their...Personal Financeread more
President Trump and Apple CEO Tim Cook have had a rocky relationship in recent years, but Trump is now complimenting the executive publicly.Technologyread more
The Food and Drug Administration is making moves to encourage the use of artificial intelligence and other digital tools in medicine and drug development, expanding a program it announced last year around digital health and establishing a new incubator focused on health technology.
"AI holds enormous promise for the future of medicine," FDA Commissioner Scott Gottlieb said in prepared remarks for the Health Datapalooza conference Thursday in Washington. "We're actively developing a new regulatory framework to promote innovation in this space, and support the use of AI-based technologies."
The agency established its pre-certification program for digital health companies last year, enabling certain firms that obtain that status to bring digital health products to market through a more streamlined regulatory process. Gottlieb said the regulatory agency will look to apply that program to tools based on AI as well.
"We expect to see an increasing number of AI-based submissions in the coming years, starting with medical imaging devices, and we're working with experts in the field," Gottlieb said.
As part of the agency's new incubator, which is called the Information Exchange and Data Transformation, or INFORMED, the FDA will focus on tools to improve cancer treatment and drug development.
The regulator cited collaborations with Project Data Sphere that aim to use medical imaging data to develop algorithms that can better classify tumors, and with the National Cancer Institute on a joint fellowship program to design "digital biomarkers" to use in drug development.
Gottlieb also said the agency will seek public input on the right way to incorporate digital health tools designed to be used with prescription drugs, and is fine-tuning the pre-certification program framework, and hopes to have that in place by the end of this year.
"We share your urgency to advance this innovation in care," Gottlieb said. "And we're committed to doing our part to support its benefits to patients."